PCM
BIVIW

Prelude Capital Management’s BioVie Inc Warrant BIVIW Stock Holding History

Prelude Capital Management’s Portfolio BIVIW Stock Details BIVIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.9K Hold
186,621
– – ﹤0.01% 1116
2025
Q4 		$48K Sell
186,621
-106,815
-36% -$35K ﹤0.01% 1239
2025
Q3 		$132K Buy
+293,436
New +$119K 0.01% 1019

Other funds holding BIVIW

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Prelude Capital Management's BIVIW Position: Q1 2026 in Review

Prelude Capital Management held its BioVie Inc Warrant (BIVIW) position steady in Q1 2026 at 186,621 shares worth $57.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

Prelude Capital Management first reported a position in BIVIW in Q3 2025 and has held it in 3 quarters since. The position peaked at $132K in Q3 2025. 8 funds tracked by Wall St. Rank hold BIVIW as of Q1 2026.

  • Prelude Capital Management held 186,621 shares of BioVie Inc Warrant worth $57.9K as of Q1 2026.
  • Prelude Capital Management left its BioVie Inc Warrant share count unchanged in Q1 2026.
  • BioVie Inc Warrant made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1116 holding.
  • Prelude Capital Management first reported a position in BioVie Inc Warrant in Q3 2025 and has held it in 3 quarters since.
  • Prelude Capital Management's BioVie Inc Warrant position peaked at $132K in Q3 2025.
  • 8 funds tracked by Wall St. Rank held BioVie Inc Warrant as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.